These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Opportunistic infections in non-human primates exposed to immunomodulatory biotherapeutics: considerations and case examples. Hutto DL J Immunotoxicol; 2010; 7(2):120-7. PubMed ID: 19909226 [TBL] [Abstract][Full Text] [Related]
43. Costimulatory Function of Cd58/Cd2 Interaction in Adaptive Humoral Immunity in a Zebrafish Model. Shao T; Shi W; Zheng JY; Xu XX; Lin AF; Xiang LX; Shao JZ Front Immunol; 2018; 9():1204. PubMed ID: 29904386 [TBL] [Abstract][Full Text] [Related]
44. Restimulation After Cryopreservation and Thawing Preserves the Phenotype and Function of Expanded Baboon Regulatory T Cells. Weiner J; Duran-Struuck R; Zitsman J; Buhler L; Sondermeijer H; McMurchy AN; Levings MK; Sykes M; Griesemer A Transplant Direct; 2015 Feb; 1(1):1-7. PubMed ID: 27019869 [TBL] [Abstract][Full Text] [Related]
45. Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. Bugelski PJ; Martin PL Br J Pharmacol; 2012 Jun; 166(3):823-46. PubMed ID: 22168282 [TBL] [Abstract][Full Text] [Related]
46. Psoriasis treatment: current and emerging directed therapies. Winterfield LS; Menter A; Gordon K; Gottlieb A Ann Rheum Dis; 2005 Mar; 64 Suppl 2(Suppl 2):ii87-90; discussion ii91-2. PubMed ID: 15708946 [TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. Vaishnaw AK; TenHoor CN J Pharmacokinet Pharmacodyn; 2002 Dec; 29(5-6):415-26. PubMed ID: 12795239 [TBL] [Abstract][Full Text] [Related]
48. Alefacept. Amevive, BG 9273, human LFA-3/Igg fusion protein, LFA 3, LFA 3 TIP LFA 3/CD2, LFA-3/Igg fusion protein, LFA3TIP, recombinant LFA-3/Igg1 human fusion protein, recombinantly engineered LFA-1/Igg1 human fusion protein. Drugs R D; 2002; 3(1):21-4. PubMed ID: 11881524 [No Abstract] [Full Text] [Related]
49. [Novel vaccines against M. tuberculosis]. Okada M Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920 [TBL] [Abstract][Full Text] [Related]
50. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. Majeau GR; Meier W; Jimmo B; Kioussis D; Hochman PS J Immunol; 1994 Mar; 152(6):2753-67. PubMed ID: 7511625 [TBL] [Abstract][Full Text] [Related]
51. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Meier W; Gill A; Rogge M; Dabora R; Majeau GR; Oleson FB; Jones WE; Frazier D; Miatkowski K; Hochman PS Ther Immunol; 1995 Jun; 2(3):159-71. PubMed ID: 8885134 [TBL] [Abstract][Full Text] [Related]
52. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. Kaplon RJ; Hochman PS; Michler RE; Kwiatkowski PA; Edwards NM; Berger CL; Xu H; Meier W; Wallner BP; Chisholm P; Marboe CC Transplantation; 1996 Feb; 61(3):356-63. PubMed ID: 8610340 [TBL] [Abstract][Full Text] [Related]
53. A novel murine model for the assessment of human CD2-related reagents in vivo. Ding Y; Qin L; Yang Q; Punch JD; Fox DA; Hochman PS; Bromberg JS J Immunol; 1996 Sep; 157(5):1863-9. PubMed ID: 8757303 [TBL] [Abstract][Full Text] [Related]